Wednesday, October 22, 2008

Valeant Pharma, GSK close worldwide pact for retigabine

Valeant Pharmaceuticals International announced that it has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline (GSK) for the investigational drug retigabine, a first-in-class neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures. Under the terms of the agreement, Valeant received an upfront payment of $125 million from GSK.

No comments: